Anzeige
Mehr »
Login
Samstag, 15.02.2025 Börsentäglich über 12.000 News von 686 internationalen Medien
1,5 Mio. Unzen indiziert, 5,2 Mio. Unzen geschätzt - und es wächst weiter: Die Goldaktie mit neuem Potenzial
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AP32 | ISIN: US74366E1029 | Ticker-Symbol: PGF
Berlin
14.02.25
21:52 Uhr
36,600 Euro
-0,200
-0,54 %
1-Jahres-Chart
PROTAGONIST THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
PROTAGONIST THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur PROTAGONIST THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
07.02.Truist maintains Buy on Protagonist Therapeutics with $60 target2
07.02.JMP Securities maintains PTGX stock with $58 target1
PROTAGONIST THERAPEUTICS Aktie jetzt für 0€ handeln
04.02.Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $53.001
30.01.Protagonist Therapeutics: Protagonist to Host Investor Event with KOL Insights on Polycythemia Vera and the Hepcidin Mimetic Rusfertide in New York on February 6, 2025384NEWARK, CALIFORNIA / ACCESS Newswire / January 29, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company")will host an in-person and virtual investor event on Thursday, February 6, 2025...
► Artikel lesen
27.01.Protagonist Therapeutics (NASDAQ:PTGX) Trading 5.6% Higher - Time to Buy?2
17.01.Protagonist Therapeutics CFO Ali Asif meldet Aktienverkauf-
17.01.Medizinischer Leiter von Protagonist Therapeutics verkauft Aktien zur Deckung von Steuerverpflichtungen-
06.01.Protagonist Therapeutics Reports Granting of Inducement Awards290NEWARK, CALIFORNIA / ACCESSWIRE / January 6, 2025 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on January 2, 2025, it issued inducement awards to Newman Yeilding, M.D., upon his...
► Artikel lesen
06.01.Protagonist Therapeutics, Inc - 8-K, Current Report1
06.01.Protagonist Therapeutics (NASDAQ:PTGX) Trading Down 4.4% - What's Next?3
19.12.24Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025267NEWARK, CA / ACCESSWIRE / December 19, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will...
► Artikel lesen
09.12.24Protagonist Therapeutics: Protagonist Reports Final Results From Rusfertide Phase 2 REVIVE Study Showing Durable Hematocrit Control at the ASH 2024 Annual Meeting31354% of patients experience more than 2.5 years of durable hematocrit (Hct) control ( NEWARK, CA / ACCESSWIRE / December 9, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced...
► Artikel lesen
22.11.24Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024276NEWARK, CA / ACCESSWIRE / November 22, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will...
► Artikel lesen
21.11.24Protagonist Therapeutics: Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate288Oral peptide with biologics-like high potency and spectrum of activity against three therapeutically relevant dimeric forms of IL-17 (AA, AF and FF)IND enabling studies underway, with Phase I initiation...
► Artikel lesen
19.11.24Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate205Webcast and conference call to be held be on Thursday, November 21st at 4:30 pm ET, dial in information belowNEWARK, CA / ACCESSWIRE / November 19, 2024 / Protagonist Therapeutics, Inc. ("Protagonist"...
► Artikel lesen
18.11.24Protagonist Therapeutics: Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra in Plaque Psoriasis, a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor319ICONIC-LEAD achieved its co-primary endpoints of PASI-90 and IGA of 0 or 1 at week 16; 74% of patients achieved clear or almost clear skin (IGA 0/1) at week 24ICONIC-TOTAL achieved its primary endpoint...
► Artikel lesen
18.11.24Protagonist Therapeutics, Inc - 8-K, Current Report3
07.11.24Protagonist Therapeutics: Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update233Top line results for JNJ-2113 Phase 3 ICONIC-LEAD and Phase 3 ICONIC-TOTAL clinical trials in patients with moderate to severe psoriasis expected in Q4 2024Top line results for JNJ-2113 Phase 2b ANTHEM...
► Artikel lesen
07.11.24Protagonist Therapeutics, Inc - 8-K, Current Report1
05.11.24Protagonist Therapeutics Announces Poster Presentation on Final REVIVE Phase 2 Study Data with Rusfertide at the 66th Annual ASH Meeting431NEWARK, CA / ACCESSWIRE / November 5, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that final data from the Phase 2 REVIVE study with rusfertide in polycythemia vera...
► Artikel lesen
Seite:  Weiter >>
47 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1